Role of immature myeloid Gr-1+ cells in the development of antitumor immunity.
D053330:4-1BB Ligand; D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D003110:Colonic Neoplasms / Q000235:genetics / Q000276:immunology* / Q000628:therapy; D003713:Dendritic Cells / Q000166:cytology* / Q000276:immunology*; D005260:Female; D015316:Genetic Therapy / Q000379:methods; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000235:genetics / Q000276:immunology; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D008822:Mice, Transgenic; D022423:Myeloid Cells / Q000166:cytology* / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D053330:4-1BB Ligand; D000911:Antibodies, Monoclonal; D007376:Interleukin-2; C505975:Tnfsf9 protein, mouse; D014409:Tumor Necrosis Factor-alpha; D016178:Granulocyte-Macrophage Colony-Stimulating Factor